BIOADVANCED SILICONE
中文 Ask BIO AI
Industry Insights

Industry Insights · Brain–Computer Interface

Xiangyu Medical bets RMB1.37bn on non-invasive BCI rehab

The 'non-invasive + rehabilitation' route for brain-computer interfaces is attracting heavy listed-company investment — it is safer, more scalable and closer to the home-rehab use case.

2026-06-21BIO Industry Insights

Non-invasive BCI rehab loop: EEG acquisition, AI decoding, rehab hardware, active interaction
Non-invasive BCI rehab loop: scalp EEG acquisition → AI decoding of movement intent → drive rehab hardware → active intent-driven training. Illustrative.
In short: STAR-Market-listed Xiangyu Medical (founded 2002, Anyang, Henan) plans a private placement to raise up to RMB1.366bn, with RMB966m for rehabilitation R&D centered on non-invasive BCI (EEG) rehab products and rehab robots, plus RMB400m for working capital. Through its Sun-BCI Lab, its multi-channel wireless EEG device exceeds 92% recognition accuracy and decodes movement intent; the raise aims to embed EEG acquisition and AI decoding into its own rehab hardware — upgrading 'passive training' to 'active intent-driven interaction' across clinic and home. On policy, China's 2026 government work report mentioned BCI for the first time and listed it as a 'future industry'.

Why 'non-invasive + rehab'

BCIs are classed by implantation as invasive, semi-invasive, non-invasive and endovascular. Non-invasive (scalp EEG) has lower bandwidth and is prone to motion/EMG noise, but is safe, low-cost and scalable — closest to rehab and home wearables, exactly where rehab-device firms like Xiangyu enter.

Rehabilitation is BCI's most realistic commercial battlefield today: turning passive limb training into 'patient-initiated, intent-driven' interaction matters more for motor recovery.

The domestic-substitution chain

High-end rehab equipment has long been foreign-dominated — costly and poorly localized. Domestic substitution is advancing across chips, electrodes, algorithms and full systems; a listed company funding R&D via placement is a key step from concept to volume production.

The BIO angle

Invasive or not, a BCI's human-machine interface depends on materials in long-term body contact: the contact surface of wearable electrodes and the insulation/encapsulation of implanted electrodes both demand biocompatible medical silicone / polymers. That is BIO's layer — supplying implant- and medical-grade silicone and selection support for neural interfaces and rehab hardware.

FAQ

What is Xiangyu's placement mainly for?

A private placement of up to RMB1.366bn, with RMB966m for non-invasive BCI rehab products and rehab robots, and RMB400m for working capital.

How does non-invasive BCI differ from invasive?

Non-invasive uses scalp EEG — safe, low-cost, scalable, but lower bandwidth; invasive gives higher signal quality but needs surgery and carries higher risk, usually as Class III implants.

What do BCI rehab devices need from materials?

Wearable-electrode contact surfaces and implanted-electrode insulation both need biocompatible medical silicone/polymers balancing flexibility and long-term stability.

Related reading

Browse all insights →

Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.

Building in China's medical-device market?

From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.

Contact BIO Silicone sourcing guide
Contact BIO